MCID: ACT177
MIFTS: 34

Acute Basophilic Leukemia

Categories: Blood diseases, Cancer diseases, Rare diseases

Aliases & Classifications for Acute Basophilic Leukemia

MalaCards integrated aliases for Acute Basophilic Leukemia:

Name: Acute Basophilic Leukemia 58 17 71

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

MESH via Orphanet 44 D015471
ICD10 via Orphanet 33 C94.7
UMLS via Orphanet 72 C0023437
Orphanet 58 ORPHA86849
UMLS 71 C0023437

Summaries for Acute Basophilic Leukemia

MalaCards based summary : Acute Basophilic Leukemia is related to acute leukemia and leukemia, acute myeloid. An important gene associated with Acute Basophilic Leukemia is GATA1 (GATA Binding Protein 1), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and NF-kappaB Signaling. The drugs Cyclophosphamide and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include myeloid, t cells and bone marrow, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 74 Acute basophilic leukemia is a rare form of acute myeloid leukemia where blasts are accompanied by... more...

Related Diseases for Acute Basophilic Leukemia

Diseases related to Acute Basophilic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 39)
# Related Disease Score Top Affiliating Genes
1 acute leukemia 28.7 MPO IL3RA GATA1 ETV6
2 leukemia, acute myeloid 27.9 MYB MPO IL3RA GATA1 ETV6
3 leukemia, chronic myeloid 27.9 MYB MPO GATA1 ETV6 CSF2RA
4 leukemia, acute lymphoblastic 27.7 MYB MPO IL3RA GATA1 ETV6
5 myelodysplastic syndrome 27.7 MYB MPO IL3RA GATA1 ETV6
6 leukemia 10.6
7 chromosomal triplication 10.2
8 urticaria 10.1
9 hereditary pulmonary alveolar proteinosis 10.0 IL3RA CSF2RA
10 down syndrome 9.9
11 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.9
12 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 9.9
13 langerhans cell histiocytosis 9.9
14 gastrointestinal ulceration, recurrent, with dysfunctional platelets 9.9
15 gastric ulcer 9.9
16 disseminated intravascular coagulation 9.9
17 thrombocytopenia 9.9
18 essential thrombocythemia 9.9
19 histiocytosis 9.9
20 peritonitis 9.9
21 mast-cell leukemia 9.9
22 exophthalmos 9.9
23 47,xyy 9.9
24 acute myeloblastic leukemia with maturation 9.9
25 cytokine deficiency 9.9
26 granulocytopenia 9.9
27 splenomegaly 9.9
28 acute liver failure 9.9
29 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 9.9 MPO ETV6
30 tonsil cancer 9.9 MYB ETV6
31 leukemia, acute lymphoblastic 3 9.7 MPO ETV6
32 pollen allergy 9.7 MPO IL3RA
33 childhood leukemia 9.6 MPO ETV6
34 precursor t-cell acute lymphoblastic leukemia 9.5 MYB MPO ETV6
35 myeloproliferative neoplasm 9.2 MPO GATA1 ETV6
36 myelofibrosis 9.2 MPO GATA1 ETV6
37 megakaryocytic leukemia 9.2 MPO IL3RA GATA1
38 aplastic anemia 9.1 MPO GATA1 CSF2RA
39 acute promyelocytic leukemia 8.9 MPO GATA1 ETV6

Graphical network of the top 20 diseases related to Acute Basophilic Leukemia:



Diseases related to Acute Basophilic Leukemia

Symptoms & Phenotypes for Acute Basophilic Leukemia

GenomeRNAi Phenotypes related to Acute Basophilic Leukemia according to GeneCards Suite gene sharing:

26 (show all 47)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-100 10.29 MYB
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-102 10.29 CSF2RA
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-115 10.29 CSF2RA
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-120 10.29 MYB
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-121 10.29 MYB
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-122 10.29 MYB
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 10.29 CSF2RA
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.29 MYB
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-146 10.29 CSF2RA
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-147 10.29 MYB
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-161 10.29 MYB
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-164 10.29 MYB
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-169 10.29 MYB
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-176 10.29 ETV6
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 10.29 MYB
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 10.29 MYB
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-198 10.29 ETV6
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 10.29 MYB
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-32 10.29 CSF2RA
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 10.29 CSF2RA
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 10.29 MYB
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-73 10.29 CSF2RA ETV6 MYB
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-83 10.29 MYB
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-86 10.29 CSF2RA
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-96 10.29 CSF2RA
26 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.98 CSF2RA
27 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.98 CSF2RA
28 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.98 CSF2RA
29 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.98 CSF2RA
30 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.98 MPO
31 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.98 CSF2RA
32 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.98 CSF2RA
33 Increased shRNA abundance (Z-score > 2) GR00366-A-153 9.98 CSF2RA
34 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.98 MPO
35 Increased shRNA abundance (Z-score > 2) GR00366-A-184 9.98 MPO
36 Increased shRNA abundance (Z-score > 2) GR00366-A-215 9.98 CSF2RA
37 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.98 CSF2RA
38 Increased shRNA abundance (Z-score > 2) GR00366-A-28 9.98 MYB
39 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.98 MPO
40 Increased shRNA abundance (Z-score > 2) GR00366-A-40 9.98 MPO
41 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.98 CSF2RA
42 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.98 MPO
43 Increased shRNA abundance (Z-score > 2) GR00366-A-65 9.98 CSF2RA
44 Increased shRNA abundance (Z-score > 2) GR00366-A-68 9.98 CSF2RA
45 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.98 MPO
46 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.98 MPO
47 Reduced mammosphere formation GR00396-S 9.02 CSF2RA ETV6 GATA1 IL18R1 IL3RA

MGI Mouse Phenotypes related to Acute Basophilic Leukemia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.55 ETV6 GATA1 IL18R1 MPO MYB
2 hematopoietic system MP:0005397 9.43 ETV6 GATA1 IL18R1 IL3RA MPO MYB
3 immune system MP:0005387 9.1 ETV6 GATA1 IL18R1 IL3RA MPO MYB

Drugs & Therapeutics for Acute Basophilic Leukemia

Drugs for Acute Basophilic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 88)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
2
Lenograstim Approved, Investigational Phase 4 135968-09-1
3
Thiotepa Approved, Investigational Phase 4 52-24-4 5453
4 Alkylating Agents Phase 4
5 Antirheumatic Agents Phase 4
6 Antilymphocyte Serum Phase 4
7
Thioguanine Approved Phase 3 154-42-7 2723601
8
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
9
Melphalan Approved Phase 2, Phase 3 148-82-3 460612 4053
10
Clofarabine Approved, Investigational Phase 2, Phase 3 123318-82-1 119182
11
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
12
Busulfan Approved, Investigational Phase 3 55-98-1 2478
13
Etoposide Approved Phase 3 33419-42-0 36462
14
Arsenic trioxide Approved, Investigational Phase 2, Phase 3 1327-53-3 518740
15
Fludarabine Approved Phase 2, Phase 3 21679-14-1, 75607-67-9 30751
16
Azacitidine Approved, Investigational Phase 2, Phase 3 320-67-2 9444
17
alemtuzumab Approved, Investigational Phase 2, Phase 3 216503-57-0
18
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
19
Daunorubicin Approved Phase 3 20830-81-3 30323
20
midostaurin Approved, Investigational Phase 3 120685-11-2 104937 9829523
21
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
22
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
23
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
24
tipifarnib Investigational Phase 2, Phase 3 192185-72-1 159324
25 N-Methylaspartate Phase 3
26 Gemtuzumab Phase 3
27 Analgesics Phase 3
28 Antineoplastic Agents, Immunological Phase 3
29 Etoposide phosphate Phase 3
30 Anti-HIV Agents Phase 3
31 Anti-Retroviral Agents Phase 3
32
asparaginase Phase 3
33 Interleukin-2 Phase 3
34 Analgesics, Non-Narcotic Phase 3
35 Antibiotics, Antitubercular Phase 3
36 Immunologic Factors Phase 3
37 Anti-Infective Agents Phase 3
38 Antiviral Agents Phase 3
39 Immunosuppressive Agents Phase 3
40 Antimetabolites Phase 3
41 Anti-Bacterial Agents Phase 3
42 Protein Kinase Inhibitors Phase 3
43 Gastrointestinal Agents Phase 3
44 Hormones Phase 3
45 Antineoplastic Agents, Hormonal Phase 3
46 Antiemetics Phase 3
47
protease inhibitors Phase 3
48 HIV Protease Inhibitors Phase 3
49 Hormone Antagonists Phase 3
50 BB 1101 Phase 3

Interventional clinical trials:

(show top 50) (show all 53)
# Name Status NCT ID Phase Drugs
1 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 Gemtuzumab Ozogamicin (GO) Monotherapy Versus Standard Supportive Care for Previously Untreated AML in Elderly Patients Who Are Not Eligible for Intensive Chemotherapy: A Randomized Phase II/III Trial (AML-19) of the EORTC-LG and GIMEMA-ALWP Unknown status NCT00091234 Phase 2, Phase 3 gemtuzumab ozogamicin
3 The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years Unknown status NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
4 A Phase III Randomized of Cloretazine™ (VNP40101M) and Cytosine Arabinoside (AraC) in Patients With Acute Myeloid Leukemia in First Relapse Completed NCT00112554 Phase 3 cytarabine;laromustine
5 A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults Completed NCT00372593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;mitoxantrone hydrochloride
6 A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg®) During Induction Therapy Versus Standard Induction With Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy With Gemtuzumab Ozogamicin (Mylotarg®) or No Additional Therapy For Patients Under Age 61 With Previously Untreated De Novo Acute Myeloid Leukemia (AML) Completed NCT00085709 Phase 3 gemtuzumab ozogamicin;Cytosine arabinoside;Daunomycin
7 Phase III Randomized Study of Induction Chemotherapy With or Without MDR-Modulation With PSC-833 (NSC # 648265, IND # 41121) Followed by Cytogenetic Risk-Adapted Intensification Therapy Followed by Immunotherapy With rIL-2 (NSC # 373364, IND # 1969) vs. Observation in Previously Untreated Patients With AML &lt; 60 Years Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
8 A Programme of Treatment Development for Older Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
9 A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML) Active, not recruiting NCT00651261 Phase 3 cytarabine;daunorubicin;midostaurin;dexamethasone acetate
10 Treatment of Relapsed Acute Myelogenous Leukemia Consisting of Intermediate Dose Cytosine Arabinoside (ARA-C) Plus Interspaced Continuous Infusion Idarubicin, Followed by Continuous Infusion of Low-Dose ARA-C, A Phase II Study by the EORTC-LCG Unknown status NCT00003758 Phase 2 cytarabine;idarubicin
11 A Phase II Study of Cloretazine® (VNP40101M) for Elderly Patients With De Novo Poor Risk Acute Myelogenous Leukemia Unknown status NCT00354276 Phase 2 cytarabine;laromustine
12 Evaluation of Allogeneic Peripheral Blood Stem Cell Transplants From a Related Donor Without Graft-Versus-Host Prophylaxis in Patients With High Risk of Relapse Completed NCT00003396 Phase 2 cyclophosphamide;melphalan
13 Phase II Study of Alvocidib (NSC 649890, Flavopiridol) in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Newly Diagnosed, Previously Untreated, Poor-Risk Acute Myelogenous Leukemias Completed NCT00407966 Phase 2 alvocidib;cytarabine;mitoxantrone hydrochloride
14 A Phase II Study of Lenalidomide (REVLIMID, NSC-703813) for Previously Untreated Non-M3, Deletion 5q Acute Myeloid Leukemia (AML) in Patients Age 60 or Older Who Decline Remission Induction Chemotherapy Completed NCT00352365 Phase 2 lenalidomide
15 A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia Completed NCT01656031 Phase 2 clofarabine;cytarabine
16 Phase 2 Study of Early Discharge and Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML Completed NCT01235572 Phase 2
17 A Phase II Trial Combining Gemtuzumab Ozogamicin (Mylotarg) With Cyclosporine for the Treatment of Relapsed Acute Myeloid Leukemia in Adults Over Age 60 Completed NCT00089050 Phase 2 cyclosporine;gemtuzumab ozogamicin
18 A Phase II Study Of Daunomycin And ARA-C, Both Given By Continous IV Infusion For Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) In Patients Of Age 56 Or Older Completed NCT00023777 Phase 2 cytarabine;daunorubicin hydrochloride
19 An Open Label Phase II Trial of Clofarabine and Temsirolimus in Older Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) Completed NCT00775593 Phase 2 clofarabine;temsirolimus
20 PHASE I-II STUDY OF IDARUBICIN, CYTARABINE AND R115777 (TIPIFARNIB, ZARNESTRA; 702818; IND 58359), A FARNESYLTRANSFERASE INHIBITOR, IN PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIAS Completed NCT00096122 Phase 1, Phase 2 cytarabine;idarubicin;tipifarnib
21 A Phase 2 Study of Imatinib Mesylate (Gleevec) as Maintenance Therapy After Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed C-kit Positive Acute Myeloid Leukemia Completed NCT00509093 Phase 2 imatinib mesylate
22 Autologous Bone Marrow Transplantation for Non-M3 Acute Myeloid Leukemia (AML) in First Remission in Patients </=60 Years of Age Using Busulfan/Fractionated Total Body Irradiation (FTBI) and VP16 as the Preparative Regimen Active, not recruiting NCT00534469 Phase 2 busulfan;cytarabine;etoposide;idarubicin
23 A Phase 2 Study of EMD 121974 as Maintenance Therapy for Patinets With Acute Myeloid Leukemia in Complete Remission Terminated NCT00089388 Phase 2 cilengitide
24 Randomized Phase II Trial of Idarubicin + Ara-C +/- Bevacizumab in Patients Age < 60 With Untreated Acute Myeloid Leukemia Terminated NCT00096148 Phase 2 idarubicin;cytarabine
25 Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Adults and Children With Relapsed or Refractory Acute Leukemias Completed NCT00293410 Phase 1 clofarabine;cyclophosphamide
26 A Phase I Dose-Escalation Study of R115777 (Tipifarnib) Plus PS-341 (Bortezomib) in Relapsed or Refractory Acute Leukemias Completed NCT00383474 Phase 1 Bortezomib;Tipifarnib
27 A Phase I Study of XK469R (NSC 698215) in Patients With Refractory Hematologic Malignancies Completed NCT00095797 Phase 1 R(+)XK469
28 A Phase I Study Of Therapy With The Farnesyl Transferase Inhibitor R115777 (Zarnestra) Combined With Conventional Induction And Consolidation Chemotherapy For Previously Untreated Patients Over Age 55 With Acute Myeloid Leukemia (AML) Completed NCT00101153 Phase 1 cytarabine;daunorubicin hydrochloride;tipifarnib
29 Phase I Dose Escalation Trial of the Raf Kinase Inhibitor BAY 43-9006 (NSC #724772) as Single Agent for Adults With Relapsed and Refractory Acute Leukemias and Chronic Myeloid Leukemia in Blast Crisis Completed NCT00131989 Phase 1 sorafenib tosylate
30 A Phase I Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia Completed NCT00295841 Phase 1 clofarabine;cytarabine
31 A Phase I Study of CLAG Regimen in Combination With Imatinib Mesylate (Gleevec) in Refractory or Relapsed Leukemias Completed NCT00258271 Phase 1 cladribine;cytarabine;imatinib mesylate
32 Phase I Study of BAY 43-9006 (NSC 724772) in Patients With Acute Leukemias, Myelodysplastic Syndromes and Chronic Myeloid Leukemia in Blast Phase Completed NCT00217646 Phase 1 Sorafenib Tosylate
33 Arsenic Trioxide, High-Dose Cytarabine and Idarubicin Induction Therapy in Previously Untreated de Novo and Secondary Adult Acute Myeloid Leukemia Patients < 60 Years Old - A Phase I Study Completed NCT00093483 Phase 1 arsenic trioxide;cytarabine;idarubicin
34 A Phase I Trial Of Sequential Administration Of Triapine (3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone) Followed By Fludarabine In Adults With Relapsed And Refractory Leukemias And Myelodysplasias Completed NCT00077558 Phase 1 fludarabine phosphate;triapine
35 A Phase I Study of 5-AZA-2'-Deoxycytidine and Depsipeptide in Patients With Relapsed/Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disease Completed NCT00114257 Phase 1 decitabine;romidepsin
36 Dose-Ranging Study of Arsenic Trioxide in Advanced Hematologic Cancers Completed NCT00003395 Phase 1 arsenic trioxide
37 A Phase I Study of Photochemically Treated Donor T-Cell Supplements in HLA Haplotype Mismatched Hematopoietic Stem Cell Transplantation Completed NCT00005092 Phase 1 Cyclophosphamide;Psoralen;Thiotepa
38 Phase I Trial and Pharmacokinetic Study of BMS-247550 (NSC 710428, Ixabepilone), an Epothilone B Analog, in Pediatric Patients With Refractory Solid Tumors and Leukemias Completed NCT00030108 Phase 1 ixabepilone
39 A Phase I Study Investigating the Combination of RAD001 With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Active, not recruiting NCT01154439 Phase 1 cytarabine;etoposide;everolimus;idarubicin;mitoxantrone hydrochloride
40 Phase I Dose-Finding Study of Eltrombopag Following High Dose Cytarabine and Mitoxantrone in Relapsed/Refractory Patients With Acute Myeloid Leukemia Terminated NCT01550185 Phase 1 eltrombopag olamine
41 A Phase I Study of Sorafenib in Combination With the Histone Deacetylase Inhibitor, Entinostat in Patients With Advanced Cancers Terminated NCT01159301 Phase 1 entinostat;sorafenib tosylate
42 A Phase I Study of PS-341 (Velcade, Bortezomib) in Combination With 17-allylamino-17-demethoxygeldanamycin (17-AAG) in Patients With Relapsed or Refractory Hematologic Malignancies Terminated NCT00103272 Phase 1 tanespimycin;bortezomib
43 A Dose Escalation Study of Flavopiridol (NSC 649890) Administered as a 30 Minute Loading Dose Followed by a 4-Hour Infusion in Patients With Relapsed and Refractory Acute Leukemias Terminated NCT00101231 Phase 1 alvocidib
44 The Genetics of "Non-Response" in Adult AML Unknown status NCT01421862
45 Pharmacogenetics of Gemtuzumab Ozogamicin (GO) Therapy in Acute Myeloid Leukemia Completed NCT01407757
46 Target: Identification for High Risk Childhood AML Based on Genome-Wide Analysis Completed NCT01076569
47 Analysis of Serum 2-Hydroxyglutarate (2HG) Levels, IDH Mutations and Clinical Outcome in Acute Myeloid Leukemia (AML) Completed NCT01385150
48 S0106B, Stem Cell Origin in AML: Prognostic and Therapeutic Implications Completed NCT01575535
49 S0106A, Proteomic Signatures Associated With Complete Response (CR) and Complete Continuous Response at One Year (CCR1) Following Cytarabine-Based Induction Chemotherapy in Younger Adult Patients (18-60 Years of Age) With a Newly Diagnosed Non-M3 AML Completed NCT01360125
50 Validation of a Classifier for the Prediction of Risk of Relapse Using Single Cell Network Profiling (SCNP) Assays for Childhood AML Completed NCT01438138

Search NIH Clinical Center for Acute Basophilic Leukemia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Thioguanine

Genetic Tests for Acute Basophilic Leukemia

Anatomical Context for Acute Basophilic Leukemia

MalaCards organs/tissues related to Acute Basophilic Leukemia:

40
Myeloid, T Cells, Bone Marrow, Bone, Liver, Testes

Publications for Acute Basophilic Leukemia

Articles related to Acute Basophilic Leukemia:

(show top 50) (show all 51)
# Title Authors PMID Year
1
Acute basophilic leukemia with U2AF1 mutation. 61
30827760 2019
2
[Philadelphia chromosome-positive acute lymphoblastic leukemia with basophilic blast features]. 61
31391365 2019
3
c-MYB and DMTF1 in Cancer. 61
30599775 2019
4
Acute basophilic leukemia associated with the t(16;21)(p11;q22)/FUS-ERG fusion gene. 61
29225830 2017
5
Acute basophilic leukemia with add(3)(q12) accompanied by histamine excess symptoms. 61
28424883 2017
6
Proposed diagnostic criteria and classification of basophilic leukemias and related disorders. 61
28090091 2017
7
Basophilia and megakaryoblastic differentiation in a case of acute myeloid leukemia: An unusual morphological combination. 61
26169238 2016
8
Acute basophilic leukemia presenting with maculopapular rashes and a gastric ulcer: A case report. 61
25364419 2014
9
Myelomastocytic leukemia: histopathological features, diagnostic criteria and differential diagnosis. 61
25025369 2014
10
Acute basophilic leukemia. 61
24949509 2014
11
A novel karyotype in acute myeloid leukemia with basophilia. 61
24552500 2014
12
Arsenic trioxide in treatment of de novo acute basophilic leukemia. 61
23422134 2013
13
A case of Langerhans cell histiocytosis following acute basophilic leukemia. 61
22895553 2013
14
Acute basophilic leukemia associated with loss of gene ETV6 and protean complications. 61
21576634 2011
15
Identification of a transforming MYB-GATA1 fusion gene in acute basophilic leukemia: a new entity in male infants. 61
21474671 2011
16
Trisomy 19 and t(9;22) in a patient with acute basophilic leukemia. 61
22937382 2011
17
Acute basophilic leukemia in an infant with proptosis. 61
21393925 2011
18
A case of acute basophilic leukemia arising from chronic myelogenous leukemia with development of t(7;8)(q32;q13). 61
18328951 2008
19
Monosomy 7 as the sole abnormality of an acute basophilic leukemia. 61
17213028 2007
20
[Picture in clinical hematology. Acute basophilic leukemia]. 61
17313070 2007
21
Imatinib resistant chronic myelogenous leukemia, BCR-ABL positive by chromosome and FISH analyses but negative by PCR, in a child progressing to acute basophilic leukemia: cytogenetic follow-up. 61
16965955 2006
22
Acute basophilic leukemia: case report. 61
15164378 2004
23
Acute basophilic leukemia with t(8;21). 61
15160925 2004
24
Differentiation of human basophils: an overview of recent advances and pending questions. 61
11927641 2002
25
Acute basophilic leukemia lacking basophil-specific antigens: the importance of cytokine receptor expression in differential diagnosis. 61
11999362 2002
26
Acute basophilic leukemia. 61
11722593 2001
27
[Basophilic differentiation of leukemic cells in a patient with acute leukemia carrying minor bcr/abl chimeric mRNA]. 61
11524847 2001
28
Acute basophilic leukemia presenting with abnormal liver function tests and the absence of blast cells in the peripheral blood. 61
10740808 2000
29
Diagnosis of acute basophilic leukemia. 61
10037024 1999
30
Protein tyrosine kinases in activation signal of human basophils through the immunoglobulin E receptor type l. 61
8604027 1996
31
An abnormal clone with monosomy 7 and trisomy 21 in the bone marrow of a child with congenital agranulocytosis (Kostmann disease) treated with granulocyte colony-stimulating factor. Evolution towards myelodysplastic syndrome and acute basophilic leukemia. 61
8536230 1995
32
Acute basophilic leukemia in a child. Anaphylactoid reaction and coagulopathy secondary to vincristine-mediated degranulation. 61
7804964 1995
33
[Acute basophilic leukemia]. 61
7847033 1994
34
[Acute basophilic leukemia with an intense erythroblastic reaction]. 61
8140501 1993
35
Acute basophilic leukemia and acute eosinophilic leukemia after therapy for non-Hodgkin's lymphoma. 61
8257517 1993
36
[Acute basophilic leukemia: a case report]. 61
7689662 1993
37
Acute basophilic leukemia. 61
1489389 1992
38
Acute basophilic leukemia. A case report. 61
1718580 1991
39
Acute basophilic leukemia. A clinical, morphologic, and cytogenetic study of eight cases. 61
1862771 1991
40
Evolution of the French-American-British (FAB) proposals. Is there a place for acute basophilic leukemia? 61
1862770 1991
41
[Atypical urticaria disclosing acute basophilic leukemia. Apropos of a case associated with hyperhistaminemia]. 61
2437851 1987
42
[Ultrastructural study of a case of acute basophilic leukemia--observation of the large membrane complexes and a hypothesis of basophil granule formation]. 61
3747173 1986
43
[Acute basophilic leukemia]. 61
3860999 1985
44
Acute basophilic leukemia. 61
6731465 1984
45
[Acute basophilic leukemia in a 75-year-old man. A clinical and cytological study with a review of the literature]. 61
6203233 1984
46
Mast cell leukemia and acute basophilic leukemia. Cytochemical studies. 61
747630 1978
47
[An autopsy case of acute basophilic leukemia (author's transl)]. 61
633630 1978
48
Follow-up of sixty two cases of acute basophilic leukemia. 61
667277 1978
49
[Acute basophilic leukemia with histamine excess symptoms (author's transl)]. 61
56471 1975
50
[Initial electron microscopy studies in 2 cases of acute basophilic leukemia]. 61
5532288 1970

Variations for Acute Basophilic Leukemia

Expression for Acute Basophilic Leukemia

Search GEO for disease gene expression data for Acute Basophilic Leukemia.

Pathways for Acute Basophilic Leukemia

GO Terms for Acute Basophilic Leukemia

Biological processes related to Acute Basophilic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of hematopoietic stem cell differentiation GO:1902036 8.62 MYB GATA1

Molecular functions related to Acute Basophilic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.33 MYB GATA1 ETV6
2 cytokine receptor activity GO:0004896 8.96 IL3RA CSF2RA
3 cytokine binding GO:0019955 8.62 IL3RA CSF2RA

Sources for Acute Basophilic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....